Anticholinergic Drug Burden in Older People's Brain - How well is it Measured?

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 2, 2014, Pages 151-159

  Kersten, Hege ^a   Wyller, Torgeir Bruun ^b,c  

^a VESTFOLD HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADVERSE OUTCOME; ANTICHOLINERGIC EFFECT; BEHAVIOR DISORDER; BRAIN; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; DELIRIUM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG USE; EMOTIONAL DISORDER; HUMAN; IN VITRO STUDY; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT;

AGED; BRAIN; CHOLINERGIC ANTAGONISTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891663154     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12140     Document Type: Review

References (72)

1. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012;60:616-31.
2. Lam MP, Cheung BM. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert Rev Clin Pharmacol 2012;5:187-97.
3. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008;56:1333-41.
4. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011;59:1477-83.
5. Kersten H, Molden E, Willumsen T, Engedal K, Wyller TB. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 2013;75:842-9.
6. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR, Carnahan RM et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006;46:1481-6.
7. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508-13.
8. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007;167:781-7.
9. Boustani M, Baker MS, Campbell N, Munger S, Hui SL, Castelluccio P et al. Impact and recognition of cognitive impairment among hospitalized elders. J Hosp Med 2010;5:69-75.
10. Forrer GR. MILLER JJ. Atropine coma: a somatic therapy in psychiatry. Am J Psychiatry 1958;115:455-8.
11. Tollefson GD, Montague-Clouse J, Lancaster SP. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991;3:314-9.
12. Tamura BK, Bell CL, Inaba M, Masaki KH. Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med 2012;28:217-36.
13. Haasum Y, Fastbom J, Johnell K. Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide register-based study. Ann Pharmacother 2012;46:339-46.
14. Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc 2001;49:277-83.
15. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005;165:808-13.
16. Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700, 000 elderly patients. Drugs Aging 2008;25:871-7.
17. Wawruch M, Macugova A, Kostkova L, Luha J, Dukat A, Murin J et al. The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiol Drug Saf 2011;21:170-6.
18. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 2009;23:257-65.
19. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59-66.
20. Nilvebrant L. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Acta Pharmacol Toxicol (Copenh) 1986;59(Suppl 1):1-45.
21. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78.
22. Scarr E. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci Ther 2012;18:369-79.
23. Aleman A. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients by K Mori et al. Pharmacopsychiatry 2003;36:43-4.
24. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009;30:87-92.
25. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008;56:2203-10.
26. Rovner BW, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care capacity and anticholinergic drug levels in nursing home patients. Am J Psychiatry 1988;145:107-9.
27. Cao YJ, Mager DE, Simonsick EM, Hilmer SN, Ling SM, Windham BG et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008;83:422-9.
28. Scheel-Kruger J. Central effects of anticholinergic drugs measured by the apomorphine gnawing test in mice. Acta Pharmacol Toxicol (Copenh) 1970;28:1-16.
29. Jakobsen SM, Kersten H, Molden E. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. J Am Geriatr Soc 2011;59:501-5.
30. Smith DO, Chapman MR. Acetylcholine receptor binding properties at the rat neuromuscular junction during aging. J Neurochem 1987;48:1834-41.
31. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992;5:72-7.
32. Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ et al. Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986;13(Suppl 4):521-7.
33. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 1987;44:418-26.
34. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf 2011;10:751-65.
35. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C et al. Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale: Results from the REPOSI Study. Drugs Aging 2013;30:103-12.
36. Tune L, Coyle JT, Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry 1980;37:293-7.
37. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.
38. Thomas C, Hestermann U, Kopitz J, Plaschke K, Oster P, Driessen M et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. BMC Neurosci 2008;9:86.
39. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003;60:198-203.
40. Mussi C, Ferrari R, Ascari S, Salviloi G. Importance of serum anticholinergic activity in the assessment of elderly patients with delirium. J Gertiatr Psychiatry Neurol 1999;12:82-6.
41. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-53.
42. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Carnahan RM, Lund BC et al. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice [Review] [46 refs]. Psychopharmacol Bull 2002;36:24-39.
43. Flacker JM, Lipsitz LA. Serum anticholinergic activity changes with acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci 1999;54:M12-6.
44. Cox EA, Kwatra SG, Shetty S, Kwatra MM. Flaws in the serum anticholinergic activity assay: implications for the study of delirium. J Am Geriatr Soc 2009;57:1707-8.
45. Summers William K. A clinical method of estimating risk of drug induced delirium. Life Sci 1978; 22:1511-6.
46. Han L, McCusker J, Cole M. Use of medications with anticholinergic effects predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-105.
47. Malone-Lee J. James Malone-Lee responds to the media flurry over safety of anticholinergic drugs in elderly people. BMJ 2011;343:d4740.
48. Duran CE, Azermai M. Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013;69:1731.
49. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009;4:225-33.
50. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry 2012;21:785-93.
51. Taekema DG, Gussekloo J, Maier AB, Westendorp RG, de Craen AJ. Handgrip strength as a predictor of functional, psychological and social health. A prospective population-based study among the oldest old. Age Ageing 2010;39:331-7.
52. Mielke MM, Roberts RO, Savica R, Cha R, Drubach DI, Christianson T et al. Assessing the Temporal Relationship Between Cognition and Gait: Slow Gait Predicts Cognitive Decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 2012;68:928-37.
53. Kumpula EK, Bell JS, Soini H, Pitkala KH, Kumpula EK, Bell JS et al. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol 2011;51:256-63.
54. Tune LE, Bylsma FW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr 1991;3:397-408.
55. Hustveit O. Interaction between opioid and muscarinic receptors in the guinea-pig ileum preparation: a mathematical model. Pharmacol Toxicol 1996;78:167-73.
56. Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE, Uusvaara J et al. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study. Drugs Aging 2011;28:131-8.
57. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006;332:455-9.
58. Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Mendiondo MS et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006;14:980-4.
59. Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Bio Sci Med Sci 2012;68:271-8.
60. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN, Gnjidic D, Le Couteur DG et al. A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people. Ann Pharmacother 2010;44:1725-32.
61. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998;6:31-41.
62. Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci 2007;62:83-5.
63. Chew ML, Mulsant BH, Pollock BG, Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry 2005;13:535-8.
64. Nebes RD, Pollock BG, Halligan EM, Houck P, Saxton JA, Nebes RD et al. Cognitive slowing associated with elevated serum anticholinergic activity in older individuals is decreased by caffeine use. Am J Geriatr Psychiatry 2011;19:169-75.
65. Juliebo V, Bjoro K, Krogseth M, Skovlund E, Ranhoff AH, Wyller TB. Risk factors for preoperative and postoperative delirium in elderly patients with hip fracture. J Am Geriatr Soc 2009;57:1354-61.
66. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the ageing brain: a review and practical application. Ageing Health 2008;4:311-20.
67. Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M et al. The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study. Age Ageing 2011;40:730-5.
68. Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc 2011;59(Suppl 2):S277-81.
69. Kolanowski A, Fick DM, Campbell J, Litaker M, Boustani M. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc 2009;10:252-7.
70. Gnjidic D, Le Couteur DG, Naganathan V, Cumming RG, Creasey H, Waite LM et al. Effects of drug burden index on cognitive function in older men. J Clin Psychopharmacol 2012;32:273-7.
71. Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 2009;68:97-105.
72. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ et al. Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing 2010;39:503-7.